Cardiol Therapeutics holder reports 5.3% stake

The reported position includes shared authority over disposition of the shares and no sole or shared voting power.

Available on EDGAR 09/23/2026 - 12:17 PM EDT Accepted by SEC EDGAR 09/23/2026 - 12:16 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Cardiol Therapeutics Inc. is the issuer in an amended Schedule 13G reporting 6,382,551 Class A Common Shares, or 5.3% of the class, as beneficially owned by Trefoil Select Funds SPC-Stylus SP and its fund manager, Tejara Capital Limited. The ownership table lists zero sole and shared voting power, zero sole dispositive power, and shared dispositive power over 6,382,551 shares. Tejara Capital Limited is described as an FCA-authorised UK fund manager that manages the fund.

Key Figures

Beneficially owned Class A Common Shares: 6,382,551 shares Percent of class: 5.3% Shared dispositive power: 6,382,551 shares +2 more

5 metrics

Beneficially owned Class A Common Shares 6,382,551 shares Reported in the amended ownership disclosure

Percent of class 5.3% Reported beneficial ownership

Shared dispositive power 6,382,551 shares Ownership table

Sole voting power 0 shares Ownership table

Shared voting power 0 shares Ownership table

Key Terms

beneficially owned, shared dispositive power, substantially comparable

3 terms

beneficially owned regulatory

"Amount beneficially owned: 6,382,551"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared power to dispose or to direct the disposition of"

substantially comparable regulatory

"the foreign regulatory scheme ... is substantially comparable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CRDL shares are reported as beneficially owned?

The amended report lists 6,382,551 Class A Common Shares as beneficially owned, equal to 5.3% of the class.

Who reported beneficial ownership of CRDL shares?

The reporting persons are Trefoil Select Funds SPC-Stylus SP and Tejara Capital Limited. Tejara Capital Limited is described as the fund manager for Trefoil Select Funds SPC-Stylus SP.

Do the CRDL reporting persons have voting power over the shares?

The ownership table lists zero sole voting power and zero shared voting power for the reported shares.

Who has dispositive power over the reported CRDL shares?

The ownership table lists shared dispositive power over 6,382,551 shares and zero sole dispositive power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Cardiol Therapeutics Inc.

(Name of Issuer)

Class A Common Shares

(Title of Class of Securities)

14161Y200

(CUSIP Number)

09/02/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 14161Y200

1

Names of Reporting Persons

Tejara Capital Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,382,551.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,382,551.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Fund Manager authorised by FCA in UK

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cardiol Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 602-2265 UPPER MIDDLE ROAD EAST, 602-2265 UPPER MIDDLE ROAD EAST, OAKVILLE, ONTARIO, CANADA, L6H 0G5.
Item 2.
(a)	Name of person filing: i. Trefoil Select Funds SPC-Stylus SP ii. Tejara Capital Limited
(b)	Address or principal business office or, if none, residence: i. C/O Apex Funds Services Cayman Ltd, 3rd Floor, Citrus Gove Building, 106 Goring Ave, Grand Cayman, George Town KY1-1001, Cayman Islands ii. 4th Floor, 40 Grosvenor Gardens, London SW1W 0EB, United Kingdom
(c)	Citizenship: i. Cayman ii. United Kingdom
(d)	Title of class of securities: Class A Common Shares
(e)	CUSIP No.: 14161Y200
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	Tejara Capital Limited is authorised by FCA in UK as a fund manager and it manages the fund Trefoil Select Funds SPC- Stylus SP, that is registered in Cayman
Item 4.	Ownership
(a)	Amount beneficially owned: 6,382,551
(b)	Percent of class: 5.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 6,382,551
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a fund manager authorised and regulated by the FCA in the UK is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Tejara Capital Ltd

Signature:	Miyan Mansur Mannan
Name/Title:	DIRECTOR
Date:	09/23/2026